New Delhi: In a significant development in the high-stakes patent litigation over diabetes blockbuster Semaglutide, the Delhi High Court has refused to grant Danish innovator Novo Nordisk an interim injunction to restrain Dr Reddy's Laboratories from manufacturing the drug in India.

The suit pertains to Patent No. 262697, a species patent covering Semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus. Novo Nordisk approached the court after discovering that Dr Reddy’s and its associate, OneSource Specialty Pharma, had begun manufacturing and exporting Semaglutide in early 2025, allegedly infringing the patent that expires on March 26, 2026.

Justice Manmeet Pritam Singh Arora heard the matter across several dates — July 31, August 1, August 8, August 22, August 27, Septembe

See Full Page